All In Biotech

Drug Trial Radar · NCT04580745

Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers

A Phase 1a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Oral MORF-057 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

67

Actual

Start

Sep 23, 2020

Primary completion

Mar 31, 2021

Study completion Apr 12, 2021

Sponsor

Sponsor type
Industry
First posted
Oct 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase 1a randomized, double-blind, placebo-controlled study to evaluate single and multiple ascending doses of MORF-057 in healthy subjects.

Conditions

  • Healthy Volunteers

Interventions

  • MORF-057Drug

    SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057. Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states. MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057.

  • Placebo for MORF-057Drug

    SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo. MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events and safety signals observed during single and multiple ascending doses of MORF-057 administered orally to healthy adult subjectsTime frame: Day -1 to Day 28
  2. Maximum Plasma Concentration (Cmax) of MORF-057 in a fed stateTime frame: Day -1 to Day 28
  3. Time to Reach Cmax (Tmax) of MORF-057 in a fed stateTime frame: Day -1 to Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medpace

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.